Clinical trial
A Study to Examine the Effects of an Experimental Drug on Postmenopausal…
NCT00112437 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT00112437 |
|---|---|
| Title | A Study to Examine the Effects of an Experimental Drug on Postmenopausal Osteoporosis (MK-0822-004) |
| Official title | A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, and Efficacy of MK-0822 (Cathepsin K Inhibitor) in the Treatment of Postmenopausal Women With Osteoporosis |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Osteoporosis |
| Intervention type | Dietary Supplement, Drug |
| Interventions | Odanacatib, Vitamin D3, Calcium Carbonate, Placebo |
| Enrollment | 399 |
| Start date | Jun 24, 2005 |
| Primary completion | Dec 26, 2007 |
| Completion | Jan 20, 2016 |
| First posted | Jun 3, 2005 |
| Last update posted | Jan 24, 2018 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: